<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659384</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1508</org_study_id>
    <secondary_id>2015-004601-17</secondary_id>
    <nct_id>NCT02659384</nct_id>
  </id_info>
  <brief_title>Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II study, aimed at evaluating the efficacy (through progression&#xD;
      free survival at 6 months) and safety of 5 different treatments involving atezolizumab,&#xD;
      bevacizumab and/or acetylsalicylic acid in advanced recurrent platinum-resistant ovarian&#xD;
      cancer patients in order to select the optimal treatments for further development in Phase&#xD;
      III.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) at 6 months assessed by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>6 months</time_frame>
    <description>Progression Free Survival at 6 months assessed by local investigator</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atezolizumab + bevacizumab + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atezolizumab + bevacizumab + acetylsalicylic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>atezolizumab + bevacizumab + acetylsalicylic acid</arm_group_label>
    <arm_group_label>atezolizumab + bevacizumab + placebo</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atezolizumab</intervention_name>
    <arm_group_label>atezolizumab + bevacizumab + acetylsalicylic acid</arm_group_label>
    <arm_group_label>atezolizumab + bevacizumab + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <arm_group_label>atezolizumab + bevacizumab + acetylsalicylic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>atezolizumab + bevacizumab + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recurrent, histologically proven, platinum-resistant, epithelial ovarian, fallopian tube&#xD;
        and primary peritoneal cancer in advanced or metastatic stage. Histological diagnosis by&#xD;
        image guided biopsy, laparoscopy or laparotomy. Tumors diagnosed on cytology only and&#xD;
        borderline tumors are excluded.&#xD;
&#xD;
        At least one lesion accessible to biopsy without putting patient at risk&#xD;
&#xD;
        WHO PS: 0-2 for patients having received no more than two previous lines of therapy. WHO&#xD;
        PS: 0-1 for patients having received &gt;2 previous lines of therapy&#xD;
&#xD;
        Prior chemotherapy or bevacizumab:&#xD;
&#xD;
        Any number of platinum-based chemotherapy lines are allowed but a maximum of 2 previous&#xD;
        non-platinum containing lines&#xD;
&#xD;
        Prior treatment with bevacizumab or other targeted agents against Vascular Endothelial&#xD;
        Growth Factor (VEGF) or VEGF receptor is allowed, but at least 18 weeks must have elapsed&#xD;
        since their last administration&#xD;
&#xD;
        Eligible patients with ≤ 2 previous treatment lines must have been previously exposed to&#xD;
        bevacizumab or other targeted agents against VEGF or VEGF receptor&#xD;
&#xD;
        Patients may have had prior therapy providing the following conditions are met:&#xD;
&#xD;
        Radiation therapy: wash-out period of 14 days prior to the first study treatment;&#xD;
        exception: single fraction radiotherapy with the indication of pain control&#xD;
&#xD;
        Systemic anti-tumor therapy: wash-out period of 21 days prior to the first study treatment&#xD;
&#xD;
        Recovery from any toxic effects of prior therapy to ≤ Grade 1 per the National Cancer&#xD;
        Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) except fatigue&#xD;
        or alopecia.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Age &lt;18 years&#xD;
&#xD;
        Life expectancy of &lt; 12 weeks&#xD;
&#xD;
        No adequate hematologic and end organ function&#xD;
&#xD;
        Use of acetylsalicylic acid, NSAIDs or other COX-2 inhibitors that cannot be stopped at&#xD;
        baseline and for the whole duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana- Banerjee</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden Hospital - UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Coukos</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois - Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Paris - Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé Saint-Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum - Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc - Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois - Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Sutton, Surrey</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

